Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cabozantinib
Drug ID BADD_D00330
Description Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.[L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Indications and Usage For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
Marketing Status Prescription
ATC Code L01EX07
DrugBank ID DB08875
KEGG ID D10062
MeSH ID C558660
PubChem ID 25102847
NDC Product Code 42388-011; 42388-025; 42388-023; 42388-013; 42388-024; 42388-012
Synonyms cabozantinib | Cometriq | XL 184 | XL184 cpd | XL-184 | BMS 907351 | BMS907351 | BMS-907351
Chemical Information
Molecular Formula C28H24FN3O5
CAS Registry Number 849217-68-1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.0010.001865%
Abdominal pain07.01.05.0020.009058%
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; Available
Abscess11.01.08.001--Not Available
Acne23.02.01.0010.002131%Not Available
Activated partial thromboplastin time shortened13.01.02.020--Not Available
Acute hepatic failure09.01.03.0010.000208%Not Available
Acute myocardial infarction02.02.02.001; Available
Acute respiratory failure22.02.06.001; Available
Ageusia17.02.07.001; Available
Alanine aminotransferase abnormal13.03.01.0010.000799%Not Available
Alanine aminotransferase increased13.03.01.0030.008525%
Altered state of consciousness19.07.01.003; Available
Ammonia increased13.03.01.0230.001066%Not Available
Amylase increased13.05.01.0090.000799%
Anal fissure07.03.01.002--
Anal fistula07.11.05.0020.000799%
Angina pectoris24.04.04.002;
Angioedema23.04.01.001; Available
Aortic thrombosis24.01.09.0010.000533%Not Available
Aphthous ulcer07.05.06.0020.001598%Not Available
Arterial thrombosis24.01.01.002--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 16 Pages